Astex Pharmaceuticals Announces December 14th Analyst and Investor Day Agenda

        Print
| Source: Astex Pharmaceuticals, Inc.

DUBLIN, Calif., Dec. 4, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, today announced the agenda for its Analyst and Investor Day webcast, to take place from 10 am to 12:15 pm GMT on Friday, December 14th in London, UK.

Investors and interested parties may access the webcast in the Investor Events section of the Company's website, www.astx.com. A webcast replay will be available for 90 days following the live event.

     
10:00 (5 min.)   Welcome and Introductions Timothy L. Enns
    SVP, Corporate Communications and Marketing
     
10:05 (10 min.)  Corporate Overview James S.J. Manuso, PhD, MBA
    Chairman and Chief Executive Officer
     
10:15 (20 min.) Clinical Update Mohammad Azab, MD, M Sc, MBA
    Chief Medical Officer
     
10:35 (25 min.) AT13387 & Prostate Cancer Johann de Bono, MD, PhD
    Royal Marsden Hospital
    Institute of Cancer Research (ICR)
     
11:00 (25 min.) SGI-110 & Ovarian Cancer  Robert Brown, PhD
    Imperial College London
    Institute of Cancer Research (ICR)
     
11:25 (20 min.) Research & Discovery Harren Jhoti, PhD
    President and Director
     
11:45 (15 min.) Partnering & Corporate Development Martin Buckland, DPhil, MBA
    Chief Business Officer
     
12:00 (10 min.)  Financial Overview Michael Molkentin, CPA
    Chief Financial Officer and Corporate Secretary
     
12:10 (5 min.) Closing Remarks James S.J. Manuso, PhD, MBA
    Chairman and Chief Executive Officer

The times listed above are approximate and are subject to change.

About Astex Pharmaceuticals

Astex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed DACOGEN® (decitabine) for Injection and receives significant royalties on global sales.

For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.

The Astex Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12273

Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications & Marketing
Tel: +1 (925) 560-2810
E-mail: 

Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: +1 (925) 560-2845
E-mail: 

Alan Roemer
The Trout Group
Managing Director
Tel: +1 (646) 378-2945
E-mail: 

Kari Watson
MacDougall Biomedical Communications
Senior Vice President
Tel: +1 (781) 235-3060
E-mail: